Science

Jun 18, 2025, 13:03

Myeloma Paper of the Day, June 18th, suggested by Robert Orlowski

Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:

“Myeloma Paper of the Day: Phase 2 study of dara/thal/dex in relapsed and/or refractory MM finds median PFS 16 months (9.4 if thal/len/pom refractory), ORR 82% (64% VGPR or better, 25% CR or better, 13% sCR), median DOR 19 mos, median OS 32.5 mos.”

Title: A phase 2 study of Daratumumab with Thalidomide and dexamethasone in relapsed and/or Refractory Myeloma (RRMM)

Authors: Chandramouli Nagarajan, Wei-Ying Jen, Melissa Ooi, Sanjay De Mel, Cinnie Soekojo, Sung Soo Yoon, Melinda Tan, Yunxin Chen, Xinhua Li, Yogesh Pokharkar, Shi Ning Tham, Nur Shahidah Binte Hashim, Neha Awasthi, Sarah M. Burkill, Brian Durie, Wee Joo Chng

You can read the Full Article in the Blood Cancer Journal.

More posts featuring Robert Orlowski.

Blood Cancer Journal Brian Durie cancer Chandramouli Nagarajan Cinnie Soekojo Melinda Tan Melissa Ooi Myeloma Myeloma Paper of the Day Neha Awasthi Nur Shahidah Binte Hashim OncoDaily Oncology Robert Orlowski RRMM Sanjay De Mel Sarah M. Burkill Shi Ning Tham Sung-Soo Yoon Wee Joo Chng Wei Ying Jen Xinhua Li Yogesh Pokharkar Yunxin Chen

King Albert II’s Brave Battle: A Decade of Fighting Skin Cancer

25 Posts Not To Miss From ESMO GI 2025

Botensilimab and Balstilimab Show Durable Survival in MSS Colorectal Cancer: ESMO GI 2025 Update

Julian McMahon Dies at 56: A Look Back at His Private Cancer Battle and Legendary Acting Career

Vivek Subbiah: It’s Time We Evolve WHO Cancer Classification